Naptumomab estafenatox: a new immunoconjugate.

Robinson MK; Alpaugh RK; Borghaei H

首页> 外文期刊>Expert opinion on biological therapy >Naptumomab estafenatox: a new immunoconjugate.

【24h】

Naptumomab estafenatox: a new immunoconjugate.

机译：Naptumomab estafenatox：一种新的免疫偶联物。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

IMPORTANCE OF THE FIELD: New agents that specifically engage the immune system are being tested in a variety of malignancies. This review provides an overview of naptumomab, an immunotoxin, with encouraging clinical activity in Phase I trials. AREAS COVERED IN THIS REVIEW: This review examines the preclinical and the published clinical data with regards to naptumomab. WHAT THE READER WILL GAIN: This review provides the reader with an understanding of the mechanism of action, immunology, pharmacokinetics and clinical activity of this agent. TAKE HOME MESSAGE: Naptumomab has a unique mechanism of action and appears to be an active agent in the treatment of refractory solid tumors such as renal cell carcinoma.

机译：领域的重要性：特异性参与免疫系统的新药物正在各种恶性肿瘤中进行测试。这篇综述概述了免疫毒素naptumomab，在I期试验中具有令人鼓舞的临床活性。该评价涵盖的区域：本评价检查了关于纳普单抗的临床前和已发表的临床数据。读者将会获得什么：这篇评论为读者提供了对该剂的作用机理，免疫学，药代动力学和临床活性的理解。温馨提示：Naptumomab具有独特的作用机制，似乎是治疗难治性实体瘤（例如肾细胞癌）的活性剂。

著录项

来源
《Expert opinion on biological therapy》 |2010年第2期|共7页
作者
Robinson MK; Alpaugh RK; Borghaei H;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. Naptumomab estafenatox: a new immunoconjugate. [J] . Robinson MK, Alpaugh RK, Borghaei H Expert opinion on biological therapy . 2010,第2期

机译：Naptumomab estafenatox：一种新的免疫偶联物。
2. Naptumomab estafenatox: Targeted immunotherapy with a novel immunotoxin topical collection on evolving therapies [J] . EisenT., HedlundG., ForsbergG., Current oncology reports. . 2014,第1a2期

机译：Naptumomab estafenatox：具有针对性的新型免疫毒素局部疗法的靶向免疫疗法
3. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity. [J] . Forsberg G, Skartved NJ, Wallen Ohman M, Journal of immunotherapy . 2010,第5期

机译：Naptumomab estafenatox，一种工程化的抗体-超抗原融合蛋白，具有低毒性和降低的抗原性。
4. Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α [O] . Eyad Elkord, Deborah J. Burt, Anette Sundstedt, 2015

机译：来自Naptumomab estafenatox加IFN-α与IFN-α的随机2/3期研究的一部分晚期肾细胞癌患者的免疫应答和总生存率
5. A randomized phase II/III study of naptumomab estafenatox + IFNα versus IFNα in renal cell carcinoma : Final analysis with baseline biomarker subgroup and trend analysis [O] . Hawkins, Robert E., Gore, Martin, Shparyk, Yaroslav, 2016

机译：一项关于肾细胞癌中naptumomab estafenatox +IFNα与IFNα的随机II / III期研究：基线生物标志物亚组的最终分析和趋势分析

Naptumomab estafenatox: a new immunoconjugate.

摘要

著录项

相似文献

相关主题

期刊订阅